Please login to the form below

Not currently logged in
Email:
Password:

alemtuzumab

This page shows the latest alemtuzumab news and features for those working in and with pharma, biotech and healthcare.

After some big setbacks, Sanofi talks up its R&D portfolio

After some big setbacks, Sanofi talks up its R&D portfolio

It also has high hopes for alemtuzumab in primary progressive MS, Regeneron-partnered cemiplimab for first-line non-small cell lung cancer and SAR425899, a GLP-1/GCR dual agonist that

Latest news

More from news
Approximately 7 fully matching, plus 22 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics